logo-loader
viewIQ-AI Limited

IQ-AI soars as StoneChecker software gets US FDA sign-off

Imaging Biometrics, the company’s Milwaukee-based subsidiary, was granted “clearance to market” by the regulator

IQ-AI Limited -

IQ-AI Ltd (LON:IQAI) said it has received the regulatory green light in America for its StoneChecker software, which is used to assess kidney stones.

Imaging Biometrics, the company’s Milwaukee-based subsidiary, was granted “clearance to market” by the US Food & Drug Administration.

The company said it would issue an update outlining the scale of the opportunity along with its product roll-out plans in the next few days.

IQ-AI shares surged 41% to 6.65p on Friday morning.

-- Adds shares price --

Quick facts: IQ-AI Limited

Price: 4.61 GBX

LSE:IQAI
Market: LSE
Market Cap: £6.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IQ-AI's Imaging Biometrics developing technology that could 'revolutionise...

Michael Schmainda, co-founder and CEO of IQ-AI Limited's (LON:IQAI) subsidiary Imaging Biometrics tells Proactive London's Andrew Scott they're developing a technology that could revolutionise the detection and treatment of brain tumours. IB CAD has been created to pick up cancer cells before...

4 weeks ago

2 min read